MIRATI THERAPEUTICS INC's ticker is MRTX and the CUSIP is 60468T105. A total of 237 filers reported holding MIRATI THERAPEUTICS INC in Q4 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.6%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $898 | +24.2% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q2 2023 | $723 | -0.4% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q1 2023 | $726 | -14.1% | 20,000 | 0.0% | 0.00% | 0.0% |
| Q4 2022 | $845 | -100.0% | 20,000 | -46.1% | 0.00% | -75.0% |
| Q3 2022 | $2,564,000 | +4.0% | 37,140 | 0.0% | 0.01% | +14.3% |
| Q2 2022 | $2,465,000 | -24.9% | 37,140 | -4.5% | 0.01% | -12.5% |
| Q1 2022 | $3,284,000 | -42.1% | 38,890 | -1.5% | 0.01% | -42.9% |
| Q4 2021 | $5,676,000 | -4.4% | 39,490 | +15.5% | 0.01% | -17.6% |
| Q3 2021 | $5,936,000 | +8.3% | 34,190 | 0.0% | 0.02% | +6.2% |
| Q2 2021 | $5,480,000 | -2.9% | 34,190 | 0.0% | 0.02% | -15.8% |
| Q1 2021 | $5,643,000 | +13.8% | 34,190 | +51.4% | 0.02% | 0.0% |
| Q4 2020 | $4,960,000 | +9.1% | 22,590 | -18.0% | 0.02% | -5.0% |
| Q3 2020 | $4,545,000 | +196.5% | 27,550 | +105.6% | 0.02% | +100.0% |
| Q2 2020 | $1,533,000 | +112.3% | 13,400 | +52.7% | 0.01% | +66.7% |
| Q1 2020 | $722,000 | – | 8,775 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Aviva Holdings Ltd. | 3,135,966 | $136,602,679 | 87.83% |
| EcoR1 Capital, LLC | 5,748,399 | $250,400,260 | 8.45% |
| Boxer Capital, LLC | 3,201,440 | $139,454,726 | 7.42% |
| RTW INVESTMENTS, LP | 6,768,514 | $294,836,470 | 6.22% |
| Paradigm Biocapital Advisors LP | 1,668,116 | $72,663,133 | 4.93% |
| Avoro Capital Advisors LLC | 6,666,666 | $290,399,971 | 4.53% |
| Octagon Capital Advisors LP | 655,051 | $28,534,022 | 4.38% |
| Artal Group S.A. | 2,024,226 | $88,175 | 3.78% |
| Ally Bridge Group (NY) LLC | 70,283 | $3,061,527 | 3.59% |
| INTERNATIONAL BIOTECHNOLOGY TRUST PLC | 216,000 | $9,404,640 | 3.17% |